Keyphrases
Taiwan
100%
Breast Cancer
100%
Genetic Modification
100%
Tumor Genomics
100%
Comprehensive Genomic Profiling
100%
BRCA1, BRCA2
66%
Low-risk Group
50%
Disease Relapse
50%
Fibroblast Growth Factor Receptor 1 (FGFR1)
33%
Targeted Sequencing
33%
Molecular Targets
33%
ErbB2
33%
PIK3CA
33%
Clinical Actionability
33%
High-risk Population
16%
Genomic Profiling
16%
High Risk
16%
Taiwanese
16%
Breast Cancer Patients
16%
Sequence Analysis
16%
Putative Drug Targets
16%
Follow-up Time
16%
Breast Cancer Subtypes
16%
Advanced Disease
16%
Poor Outcome
16%
Molecular Alterations
16%
Metastatic Disease
16%
Neoadjuvant Chemotherapy
16%
Curative Surgery
16%
Oncogenic mutations
16%
Clinical High Risk
16%
Adjuvant Chemotherapy
16%
Early Relapse
16%
Advanced or Metastatic
16%
Actionable mutations
16%
Actionable Genes
16%
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
100%
BRCA1
50%
Low Risk Population
37%
Fibroblast Growth Factor Receptor 1
25%
Diseases
25%
Prevalence
12%
Metastatic Carcinoma
12%
Epidermal Growth Factor Receptor 2
12%
High Risk Population
12%
Gamma Urogastrone
12%
Neoadjuvant Chemotherapy
12%
Adjuvant Chemotherapy
12%
Biochemistry, Genetics and Molecular Biology
BRCA1
100%
Genomics
100%
Low Risk Population
75%
Fibroblast Growth Factor Receptor 1
50%
Genetics
25%
Prevalence
25%
Epidermal Growth Factor Receptor
25%
High Risk Population
25%
Immunology and Microbiology
Low Risk Population
100%
Fibroblast Growth Factor Receptor 1
66%
Prevalence
33%
High Risk Population
33%
Gamma Urogastrone
33%